Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens

Mariangela Manzoni, Sara Delfanti, Bianca Rovati, Donatella Grasso, Sara Mariucci, Katia Bencardino, Carmine Tinelli, Marco Danova

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The primary use of recombinant granulocyte colony-stimulating factors has reduced the incidence of febrile neutropenia during dose-dense adjuvant/neoadjuvant chemotherapy programs for breast cancer. Otherwise, in this population, filgrastim seems to worse chemotherapy- induced anemia, especially when administered with prolonged schedules that induced leukocytosis. No exhaustive data are available about the effect of longlasting formulation of filgrastim (pegfilgrastim) on hemoglobin levels. We retrospectively analyzed the data regarding hemoglobin level and leukocyte count of 38 breast cancer patients treated with dose-dense anthacycline and/or taxane-based chemotherapy with pegfilgrastim support, both in adjuvant and in neoadjuvant settings. Mean hemoglobin levels progressively decreased throughout the treatment (without correlation with both the schedule of chemotherapy and the patient's age) but only two patients developed mild anemia. No significant correlation was found between the degree of leukocytosis and the hemoglobin decrease. These data suggest that pegfilgrastim, per se, doesn't seem to worse chemotherapyinduced anemia. This fact may be at least in part explains by its ''balanced" impact on hematopoietic recovery during dose-dense chemotherapy.

Original languageEnglish
Pages (from-to)135-138
Number of pages4
JournalClinical and Experimental Medicine
Volume10
Issue number2
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Chemotherapy
Anemia
Hemoglobins
Breast Neoplasms
Drug Therapy
Leukocytosis
Appointments and Schedules
Febrile Neutropenia
Granulocyte Colony-Stimulating Factor
Adjuvant Chemotherapy
Leukocyte Count
pegfilgrastim
Incidence
Recovery
Population
Filgrastim
Therapeutics

Keywords

  • Anemia
  • Breast cancer
  • Dose-dense chemotherapy
  • Pegfilgrastim

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens. / Manzoni, Mariangela; Delfanti, Sara; Rovati, Bianca; Grasso, Donatella; Mariucci, Sara; Bencardino, Katia; Tinelli, Carmine; Danova, Marco.

In: Clinical and Experimental Medicine, Vol. 10, No. 2, 06.2010, p. 135-138.

Research output: Contribution to journalArticle

@article{2e00a7f20cc7405f93c0d3e48ebe67f1,
title = "Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens",
abstract = "The primary use of recombinant granulocyte colony-stimulating factors has reduced the incidence of febrile neutropenia during dose-dense adjuvant/neoadjuvant chemotherapy programs for breast cancer. Otherwise, in this population, filgrastim seems to worse chemotherapy- induced anemia, especially when administered with prolonged schedules that induced leukocytosis. No exhaustive data are available about the effect of longlasting formulation of filgrastim (pegfilgrastim) on hemoglobin levels. We retrospectively analyzed the data regarding hemoglobin level and leukocyte count of 38 breast cancer patients treated with dose-dense anthacycline and/or taxane-based chemotherapy with pegfilgrastim support, both in adjuvant and in neoadjuvant settings. Mean hemoglobin levels progressively decreased throughout the treatment (without correlation with both the schedule of chemotherapy and the patient's age) but only two patients developed mild anemia. No significant correlation was found between the degree of leukocytosis and the hemoglobin decrease. These data suggest that pegfilgrastim, per se, doesn't seem to worse chemotherapyinduced anemia. This fact may be at least in part explains by its ''balanced{"} impact on hematopoietic recovery during dose-dense chemotherapy.",
keywords = "Anemia, Breast cancer, Dose-dense chemotherapy, Pegfilgrastim",
author = "Mariangela Manzoni and Sara Delfanti and Bianca Rovati and Donatella Grasso and Sara Mariucci and Katia Bencardino and Carmine Tinelli and Marco Danova",
year = "2010",
month = "6",
doi = "10.1007/s10238-009-0072-y",
language = "English",
volume = "10",
pages = "135--138",
journal = "Zeitschrift für Die Gesamte Experimentelle Medizin",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",
number = "2",

}

TY - JOUR

T1 - Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens

AU - Manzoni, Mariangela

AU - Delfanti, Sara

AU - Rovati, Bianca

AU - Grasso, Donatella

AU - Mariucci, Sara

AU - Bencardino, Katia

AU - Tinelli, Carmine

AU - Danova, Marco

PY - 2010/6

Y1 - 2010/6

N2 - The primary use of recombinant granulocyte colony-stimulating factors has reduced the incidence of febrile neutropenia during dose-dense adjuvant/neoadjuvant chemotherapy programs for breast cancer. Otherwise, in this population, filgrastim seems to worse chemotherapy- induced anemia, especially when administered with prolonged schedules that induced leukocytosis. No exhaustive data are available about the effect of longlasting formulation of filgrastim (pegfilgrastim) on hemoglobin levels. We retrospectively analyzed the data regarding hemoglobin level and leukocyte count of 38 breast cancer patients treated with dose-dense anthacycline and/or taxane-based chemotherapy with pegfilgrastim support, both in adjuvant and in neoadjuvant settings. Mean hemoglobin levels progressively decreased throughout the treatment (without correlation with both the schedule of chemotherapy and the patient's age) but only two patients developed mild anemia. No significant correlation was found between the degree of leukocytosis and the hemoglobin decrease. These data suggest that pegfilgrastim, per se, doesn't seem to worse chemotherapyinduced anemia. This fact may be at least in part explains by its ''balanced" impact on hematopoietic recovery during dose-dense chemotherapy.

AB - The primary use of recombinant granulocyte colony-stimulating factors has reduced the incidence of febrile neutropenia during dose-dense adjuvant/neoadjuvant chemotherapy programs for breast cancer. Otherwise, in this population, filgrastim seems to worse chemotherapy- induced anemia, especially when administered with prolonged schedules that induced leukocytosis. No exhaustive data are available about the effect of longlasting formulation of filgrastim (pegfilgrastim) on hemoglobin levels. We retrospectively analyzed the data regarding hemoglobin level and leukocyte count of 38 breast cancer patients treated with dose-dense anthacycline and/or taxane-based chemotherapy with pegfilgrastim support, both in adjuvant and in neoadjuvant settings. Mean hemoglobin levels progressively decreased throughout the treatment (without correlation with both the schedule of chemotherapy and the patient's age) but only two patients developed mild anemia. No significant correlation was found between the degree of leukocytosis and the hemoglobin decrease. These data suggest that pegfilgrastim, per se, doesn't seem to worse chemotherapyinduced anemia. This fact may be at least in part explains by its ''balanced" impact on hematopoietic recovery during dose-dense chemotherapy.

KW - Anemia

KW - Breast cancer

KW - Dose-dense chemotherapy

KW - Pegfilgrastim

UR - http://www.scopus.com/inward/record.url?scp=77954667570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954667570&partnerID=8YFLogxK

U2 - 10.1007/s10238-009-0072-y

DO - 10.1007/s10238-009-0072-y

M3 - Article

VL - 10

SP - 135

EP - 138

JO - Zeitschrift für Die Gesamte Experimentelle Medizin

JF - Zeitschrift für Die Gesamte Experimentelle Medizin

SN - 1591-8890

IS - 2

ER -